{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:30:42Z","timestamp":1793413842666,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.gassur.2026.102640","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:48:37Z","timestamp":1791960517000},"page":"102640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["When to operate after neoadjuvant therapy for borderline resectable pancreatic cancer: a critical review and multidimensional decision framework"],"prefix":"10.1016","volume":"30","author":[{"given":"WaiSan","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenChao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianLu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunChao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib2","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.gassur.2026.102640_bib3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/jcm14041167","article-title":"Multidisciplinary therapeutic approaches to pancreatic cancer according to the resectability status","volume":"14","author":"Mauro","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.gassur.2026.102640_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.gassur.2026.102640_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102640_bib6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis","volume":"110","author":"Brown","year":"2022","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.gassur.2026.102640_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gassur.2026.102640_bib9","article-title":"NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 2.2026","year":"2026","journal-title":"Natl Compr Cancer Netw"},{"issue":"11","key":"10.1016\/j.gassur.2026.102640_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gassur.2026.102640_bib11","series-title":"Guidelines of Chinese society of clinical oncology (CSCO) pancreatic cancer","first-page":"96","year":"2024"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib12","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1097\/JS9.0000000000001313","article-title":"Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials","volume":"110","author":"He","year":"2024","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jso.25183","article-title":"Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy","volume":"118","author":"Cools","year":"2018","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1245\/s10434-014-3486-z","article-title":"Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival","volume":"21","author":"Rose","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.gassur.2026.102640_bib16","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for cancer: a trigger for metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00330-020-07433-0","article-title":"CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis","volume":"31","author":"Park","year":"2021","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102640_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tranon.2018.01.018","article-title":"Correlation of ADC with pathological treatment response for radiation therapy of pancreatic cancer","volume":"11","author":"Dalah","year":"2018","journal-title":"Transl Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jhbp.430","article-title":"Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma","volume":"24","author":"Okada","year":"2017","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00423-020-01857-4","article-title":"Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial)","volume":"405","author":"Okada","year":"2020","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.gassur.2026.102640_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejro.2024.100553","article-title":"Imaging of pancreatic ductal adenocarcinoma - an update for all stages of patient management","volume":"12","author":"Bilreiro","year":"2024","journal-title":"Eur J Radiol Open"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib23","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00261-018-1867-7","article-title":"Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI","volume":"44","author":"Riviere","year":"2019","journal-title":"Abdom Radiol (NY)"},{"issue":"9","key":"10.1016\/j.gassur.2026.102640_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.6004\/jnccn.2022.7041","article-title":"FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable\/locally advanced pancreatic adenocarcinoma","volume":"20","author":"Abdelrahman","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2214\/AJR.20.24567","article-title":"Borderline resectable and locally advanced pancreatic cancer: FDG PET\/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival","volume":"217","author":"Panda","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40644-023-00565-8","article-title":"Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET\/MRI and CA 19-9","volume":"23","author":"Yoo","year":"2023","journal-title":"Cancer Imaging"},{"issue":"8","key":"10.1016\/j.gassur.2026.102640_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLU.0000000000005300","article-title":"Integrated 68 Ga-FAPI-04 PET\/MR in pancreatic cancer: prediction of tumor response and tumor resectability after neoadjuvant therapy","volume":"49","author":"Zhang","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of 68Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","author":"R\u00f6hrich","year":"2021","journal-title":"J Nucl Med"},{"issue":"23","key":"10.1016\/j.gassur.2026.102640_bib29","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1002\/cncr.27636","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gassur.2026.102640_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.gassur.2026.102640_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000006690","article-title":"Surgery for borderline resectable and locally advanced pancreatic cancer with arterial encasement after neoadjuvant therapy: a single-center experience","author":"Ishida","year":"2025","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.pan.2020.05.020","article-title":"Clinical implications of the serum CA19-9 level in \u201cbiological borderline resectability\u201d and \u201cbiological downstaging\u201d in the setting of preoperative chemoradiation therapy for pancreatic cancer","volume":"20","author":"Takahashi","year":"2020","journal-title":"Pancreatology"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zraf033","article-title":"Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness","volume":"9","author":"Belfiori","year":"2025","journal-title":"BJS Open"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/SLA.0000000000005184","article-title":"Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma","volume":"277","author":"Newhook","year":"2023","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.gassur.2026.102640_bib36","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1245\/s10434-024-16361-y","article-title":"Neoadjuvant treatment with changes in chemotherapy regimens according to carbohydrate antigen 19-9 level for resectable\/borderline resectable pancreatic ductal adenocarcinoma","volume":"32","author":"Hashimoto","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.gassur.2026.102640_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf011","article-title":"Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study","volume":"112","author":"Dekker","year":"2025","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.gassur.2026.102640_bib39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.surg.2024.06.049","article-title":"A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer","volume":"176","author":"Akita","year":"2024","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jso.26989","article-title":"Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first","volume":"126","author":"DiPeri","year":"2022","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102640_bib41","first-page":"900","article-title":"Lewis antigen-negative pancreatic cancer: an aggressive subgroup","volume":"56","author":"Liu","year":"2020","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.gassur.2026.102640_bib42","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1245\/s10434-024-15221-z","article-title":"Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma","volume":"31","author":"Sumiyoshi","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.gassur.2026.102640_bib43","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1245\/s10434-025-17433-3","article-title":"Elevated carcinoembryonic antigen levels predict failure to reach surgery in patients with borderline resectable pancreatic cancer referred to neoadjuvant therapy","volume":"32","author":"Jacover","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib44","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1097\/SLA.0000000000004148","volume":"275","author":"Kato","year":"2022","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/SLA.0000000000006209","article-title":"Prospective evaluation of circulating tumor DNA using next-generation sequencing as a biomarker during neoadjuvant chemotherapy in localized pancreatic cancer","volume":"281","author":"Shah","year":"2025","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib46","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/SLA.0000000000006468","article-title":"New biomarkers to define a biological borderline situation for pancreatic adenocarcinoma: results of an ancillary study of the PANACHE01-PRODIGE48 trial","volume":"280","author":"Pinson","year":"2024","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","article-title":"Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy","volume":"34","author":"Janssen","year":"2021","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17625","article-title":"Pathological complete response in patients with resected pancreatic adenocarcinoma after preoperative chemotherapy","volume":"7","author":"Stoop","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pan.2023.02.005","article-title":"Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma","volume":"23","author":"Bao","year":"2023","journal-title":"Pancreatology"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib50","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.ejso.2021.12.473","article-title":"Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response","volume":"48","author":"Barrak","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"16","key":"10.1016\/j.gassur.2026.102640_bib51","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.3390\/cancers15164174","article-title":"Surgical considerations for neoadjuvant therapy for pancreatic adenocarcinoma","volume":"15","author":"Jain","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.gassur.2026.102640_bib52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.gassur.2026.102640_bib53","first-page":"487","article-title":"Nutritional support in pancreatic cancer patients and its effect on nutritional status: an observational regional HPB network study investigating current practice","volume":"32","author":"Wijma","year":"2024","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib54","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: clinical nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13741-023-00315-1","article-title":"Review of cancer therapies for the perioperative physician","volume":"12","author":"Dabo-Trubelja","year":"2023","journal-title":"Perioper Med"},{"issue":"11","key":"10.1016\/j.gassur.2026.102640_bib56","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s12094-020-02350-6","article-title":"Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer","volume":"22","author":"Martin-Perez","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib57","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1245\/s10434-026-19264-2","article-title":"Optimal time between completion of preoperative chemotherapy and surgery for locally advanced pancreatic cancer","volume":"33","author":"Cathomas","year":"2026","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.gassur.2026.102640_bib58","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.gassur.2026.102640_bib59","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ags3.12712","article-title":"Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: a multicenter single-arm phase II study (NAC-GA trial)","volume":"7","author":"Okada","year":"2023","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/cancers13010036","article-title":"Optimal preoperative multidisciplinary treatment in borderline resectable pancreatic cancer","volume":"13","author":"Kimura","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.gassur.2026.102640_bib61","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.23.01311","article-title":"Improved clinical staging system for localized pancreatic cancer using the ABC factors: a TAPS consortium study","volume":"42","author":"Dekker","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2026.102640_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.hpb.2023.01.016","article-title":"No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer","volume":"25","author":"Liu","year":"2023","journal-title":"HPB"},{"issue":"12","key":"10.1016\/j.gassur.2026.102640_bib63","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1245\/s10434-025-18084-0","article-title":"Favorable response defined by CA19-9 reduction after neoadjuvant treatment for pancreatic cancer","volume":"32","author":"Ashitomi","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2026.102640_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zraf054","article-title":"Purely resectable versus biological borderline resectable pancreatic cancer: closely related or worlds apart?","volume":"9","author":"Maggino","year":"2025","journal-title":"BJS Open"},{"issue":"2","key":"10.1016\/j.gassur.2026.102640_bib65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/diagnostics14020174","article-title":"From machine learning to patient outcomes: a comprehensive review of AI in pancreatic cancer","volume":"14","author":"Tripathi","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.gassur.2026.102640_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41698-019-0096-z","article-title":"A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer","volume":"3","author":"Nasief","year":"2019","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib67","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1186\/s12885-025-14806-5","article-title":"Radiomics analysis using machine learning to predict perineural invasion in pancreatic cancer","volume":"25","author":"Sun","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2026.102640_bib68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1148\/radiol.220329","article-title":"Artificial intelligence to predict lymph node metastasis at CT in pancreatic ductal adenocarcinoma","volume":"306","author":"Bian","year":"2023","journal-title":"Radiology"},{"issue":"13","key":"10.1016\/j.gassur.2026.102640_bib69","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/diagnostics13132183","article-title":"Predicting the efficacy of neoadjuvant chemotherapy for pancreatic cancer using deep learning of contrast-enhanced ultrasound videos","volume":"13","author":"Shao","year":"2023","journal-title":"Diagnostics"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:54:59Z","timestamp":1793411699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X26003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1091255X26003215"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102640","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When to operate after neoadjuvant therapy for borderline resectable pancreatic cancer: a critical review and multidimensional decision framework","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102640"}}